Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3906 | Taste and olfactory function evaluation Wiki | 1.00 |
| drug2506 | Nasal swab Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The investigators propose to select all COVID 19 patients attended in any health center (with in hospital beds), who have been discharged or have died at the time of the evaluation. The main objective of the present study is to carefully characterize the clinical profile of patients infected with COVID-19 in order to develop a simple prognostic clinical score allowing, in selected cases, rapid logistic decision making (discharge with follow-up, referral to provisional/field hospitals or admission to more complex hospital centers). As secondary objectives, the analysis of the risk-adjusted influence of treatments and previous comorbidities of patients infected with the disease will be performed.
Description: All cause
Measure: Death Time: through study completion, an average of 1 monthDescription: Days
Measure: In hospital stay. Time: through study completion, an average of 1 monthDescription: According the attending physician.
Measure: Heart failure Time: through study completion, an average of 1 monthDescription: According the attending physician.
Measure: Renal failure Time: through study completion, an average of 1 monthDescription: According the attending physician.
Measure: Respiratory Insufficiency. Time: through study completion, an average of 1 monthDescription: According the attending physician.
Measure: Upper respiratory tract involvement Time: through study completion, an average of 1 monthDescription: According the attending physician.
Measure: Pneumonia Time: through study completion, an average of 1 monthDescription: According the attending physician.
Measure: Sepsis Time: through study completion, an average of 1 monthDescription: According the attending physician.
Measure: Systemic inflammatory response Syndrome. Time: through study completion, an average of 1 monthDescription: According the attending physician.
Measure: Clinically relevant bleeding Time: through study completion, an average of 1 monthDescription: According the attending physician.
Measure: Other complications. Time: through study completion, an average of 1 monthAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports